Exhaled nitric oxide and carbon monoxide in lung transplanted patients

被引:13
|
作者
Cameli, P. [1 ]
Bargagli, E. [1 ]
Fossi, A. [1 ]
Bennett, D. [1 ]
Voltolini, L. [2 ]
Refini, R. M. [1 ]
Gotti, G. [3 ]
Rottoli, P. [1 ]
机构
[1] Le Scotte Hosp, Dept Med & Surg Sci & Neurosci, Resp Dis & Lung Transplantat Sect, Siena, Italy
[2] Univ Hosp Careggi, Thorac Surg, Florence, Italy
[3] Le Scote Hosp, UOC Thorac Surg, Dept Med & Surg Sci & Neurosci, Siena, Italy
关键词
Nitric oxide; Lung transplantation; Biomarker; Bronchiolitis obliterans syndrome; BRONCHIOLITIS OBLITERANS SYNDROME; MARKER; EXPRESSION;
D O I
10.1016/j.rmed.2015.07.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Exhaled nitric oxide (eNO) and carbon monoxide (eCO) are markers of pulmonary inflammation associated with acute graft rejection and lung infections in lung transplant (LTX) recipients. Regarding eNO and eCO levels in LTX patients affected by bronchiolitis obliterans syndrome (BOS), published data are discordant. Objectives: We aim to evaluate eNO at multiple flows, alveolar concentration of nitric oxide (Calv(NO)), maximum conducting airway wall flux (J'aw(NO)) and eCO levels in LTX patients to assess the potential role of these parameters in BOS evaluation. Methods: Fractional exhaled nitric oxide (FeNO), Calv(NO) and J'awNO were analysed in 30 healthy subjects and 27 stable LTX patients (12 BOS patients). Pulmonary function tests were performed after eNO and eCO assessment. Receiver operating characteristic (ROC) curves were conducted to evaluate diagnostic accuracy for BOS of eNO parameters. Results: LTX patients reported higher values of FeNO at flow rates of 50 (p < 0.01), 150 (p < 0.05), 350 ml/s (p < 0.001), and Calv(NO) (p < 0.0001) than healthy controls. BOS patients showed higher FeNO at flow rates of 150 (p < 0.05) and 350 ml/s (p < 0.01) and Calv(NO) (p < 0.001) than non-BOS patients. Calv(NO) reported a remarkable diagnostic accuracy for BOS (AUC: 0.82). There were no significant differences of eCO levels between LTX patients and healthy controls. Conclusion: LTX patients affected by BOS showed higher levels of FeNO 150 and 350, and Calv(NO) than non-BOS LTX patients, probably due to chronic airway inflammation and fibrotic remodelling. Calv(NO) may be a potential biomarker of BOS in LTX patients. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1224 / 1229
页数:6
相关论文
共 50 条
  • [41] Exhaled and nasal nitric oxide in laryngectomized patients
    Kramer, Matthias F.
    Olzowy, Bernhard
    Bihler, Annette
    de la Motte, Dorothea
    Nowak, Dennis
    Joerres, Rudolf A.
    Dressel, Holger
    BMC PULMONARY MEDICINE, 2010, 10
  • [42] Exhaled nitric oxide in patients with sleep apnea
    Agusti, AGN
    Barbé, F
    Togores, B
    SLEEP, 1999, 22 (02) : 231 - 235
  • [43] Exhaled and nasal nitric oxide in laryngectomized patients
    Matthias F Kramer
    Bernhard Olzowy
    Annette Bihler
    Dorothea de la Motte
    Dennis Nowak
    Rudolf A Jörres
    Holger Dressel
    BMC Pulmonary Medicine, 10
  • [44] CATALYZED NITRIC OXIDE REDUCTION WITH CARBON MONOXIDE
    BAKER, RA
    DOERR, RC
    INDUSTRIAL & ENGINEERING CHEMISTRY PROCESS DESIGN AND DEVELOPMENT, 1965, 4 (02): : 188 - &
  • [45] On the chemical equivalence of carbon monoxide and nitric oxide
    Manchot, W
    Pflaum, W
    BERICHTE DER DEUTSCHEN CHEMISCHEN GESELLSCHAFT, 1927, 60 : 2180 - 2182
  • [46] Diffusion capacity for nitric oxide and carbon monoxide
    Zavorsky, GS
    CHEST, 2004, 126 (05) : 1709 - 1710
  • [47] THE HOMOGENEOUS REACTION OF NITRIC OXIDE AND CARBON MONOXIDE
    FENIMORE, CP
    JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1947, 69 (12) : 3143 - 3144
  • [48] Fractionated exhaled nitric oxide in COPD patients
    Schumann, Desiree
    Kostikas, Konstantinos
    Schilter, Daniel
    Louis, Renaud
    Grize, Leticia
    Tamm, Michael
    Stolz, Daiana
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [49] Catalytic reduction of nitric oxide with carbon monoxide
    BAUERLE GL
    SERVICE GR
    NOBE K
    1971, 16 (02):
  • [50] Diffusing capacity for nitric oxide and carbon monoxide in patients with diffuse parenchymal lung disease and pulmonary arterial hypertension
    van der Lee, I
    Zanen, P
    Grutters, JC
    Snijder, RJ
    van den Bosch, JMM
    CHEST, 2006, 129 (02) : 378 - 383